中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 专题笔谈 • 上一篇    下一篇

新辅助化疗用于妇科恶性肿瘤治疗的风险与局限性

蒋芳，向阳   

  1. 作者单位：中国医学科学院 北京协和医院妇产科，北京 100730
  • 出版日期:2016-09-02 发布日期:2016-09-06
  • 通讯作者: 向阳

Deficiency of neoadjuvant chemotherapy in the treatment of gynecological malignancy.

JIANG Fang， XIANG Yang.   

  1. Department of Obstetrics and Gynecology，Peking Union Medical College Hospital，Peking Union Medical College，Chinese Academy of Medical Sciences，Beijing 100730，China
  • Online:2016-09-02 Published:2016-09-06

摘要：

新辅助化疗从20世纪80年代开始用于妇科恶性肿瘤临床。研究显示，新辅助化疗可以改善患者状态，消除远处转移病灶，缩小肿瘤直径，改善围手术期结局，提高手术切除率或满意手术的成功率。但新辅助化疗的应用也备受争议，目前最大的局限性在于其未带来明确生存获益。文章就新辅助化疗在妇科不同恶性肿瘤治疗中存在的风险和局限性进行讨论。

关键词: 新辅助化疗, 妇科恶性肿瘤, 局限性

Abstract:

Abstract:Neoadjuvant chemotherapy （NACT） was introduced to the treatment of gynecological malignancy in 1980s.Researches have shown that NACT is helpful to improve the general condition of patients，destroy the distant metastases，reduce tumor volume and，thus，improve the perioperative outcomes and increase the success rate of cytoreductive surgery.However，the therapeutic benefit of neoadjuvant chemotherapy remains controversial.A major criticism is that neoadjuvant chemotherapy fails to prove definite benefit on survival.In this article，we will discuss the limitations and deficiency of NACT in the treatment of gynecologic malignancy.

Key words: neoadjuvant chemotherapy, gynecological malignancy, deficiency

中图分类号: